China NT Pharma Group Company Limited (HKG:1011)
Hong Kong · Delayed Price · Currency is HKD 0.7200
-0.0100 (-1.37%)
Apr 2, 2026, 11:44 AM HKT
HKG:1011 Revenue
In the year 2025, China NT Pharma Group Company had annual revenue of 24.16M CNY, down -36.36%. China NT Pharma Group Company had revenue of 12.00M in the half year ending June 30, 2025, with 62.84% growth.
Revenue
24.16M CNY
Revenue Growth
-36.36%
P/S Ratio
25.42
Revenue / Employee
1.15M CNY
Employees
21
Market Cap
683.28M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.16M | -13.80M | -36.36% |
| Dec 31, 2024 | 37.96M | 30.59M | 415.34% |
| Dec 31, 2023 | 7.37M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 226.70M | 4.97M | 2.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chia Tai Enterprises International | 4.17B |
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Essex Bio-Technology | 1.81B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Dawnrays Pharmaceutical (Holdings) | 1.37B |
| Jilin Province Huinan Changlong Bio-pharmacy Company | 1.02B |
| JBM (Healthcare) | 812.98M |
| Wai Yuen Tong Medicine Holdings | 721.27M |